Tarsus Pharmaceuticals (TARS) Stock Price, Quote, News & History | Benzinga

Tarsus Pharmaceuticals Inc (TARS) Stock Price, Quote, News & History

TARSNASDAQ

Trade with Public

Trade with Public

$74.24

2.483.46%

At close: Aug 28, 5:00 PM EST

$74.24

2.483.46%

Pre-Market: 4:14 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$74.24

Volume / Avg.

0 / 937.61K

Day Range

- - -

52 Wk Range

48.20 - 85.25

Market Cap

$3.24B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

14.2%

Days to Cover

7.49

Recent Tarsus Pharmaceuticals, Inc. News

Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug

Tarsus acquires iRenix to add IRX-101, with Phase 3 planned for 2027, as William Blair calls the deal a disciplined pipeline expansion.

Vandana Singh

Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal Medicare copay scheme. Here's what you should know.

Evette Mitkov

Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday

Avi Kapoor

Top 2 Health Care Stocks That May Fall Off A Cliff In August

Avi Kapoor

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

74.16M

Investing Cash Flow (TTM)

23.85M

Financing Cash Flow (TTM)

9.38M

Free Cash Flow (TTM)

56.00M

Capital Expenditure (TTM)

-18.16M

Net Change in Cash (TTM)

107.39M

Analyst Trends and Forecast

1

May

3

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.88B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

5.26

PB Ratio (TTM)

9.40

Earnings Yield % (TTM)

-1.44%

Earnings Yield % (FWD)

-9.42%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

56.92

Book Value / Share

$7.90

Company Debt

Total Debt

$72.76M

LT Debt

$72.76M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$204.60M

Debt to Equity

0.21

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$74.24

Volume / Avg.

0 / 937.61K

Day Range

- - -

52 Wk Range

48.20 - 85.25

Market Cap

$3.24B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

14.2%

Days to Cover

7.49

About

Sector

Health Care

Industry

Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class the...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Tarsus Pharmaceuticals (TARS) stock?

A

You can purchase shares of Tarsus Pharmaceuticals (NASDAQ:TARS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Tarsus Pharmaceuticals (TARS) competitors?

A

Other companies in Tarsus Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Tarsus Pharmaceuticals (TARS) stock?

A

Tarsus Pharmaceuticals has a consensus price target of $80.70.

Q

What is the current price for Tarsus Pharmaceuticals (TARS)?

A

The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $74.24 last updated August 31, 2026 at 4:00 PM EDT.

Q

Does Tarsus Pharmaceuticals (TARS) pay a dividend?

A

There are no upcoming dividends for Tarsus Pharmaceuticals.

Q

When is Tarsus Pharmaceuticals (NASDAQ:TARS) reporting earnings?

A

Tarsus Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Tarsus Pharmaceuticals (TARS) going to split?

A

There is no upcoming split for Tarsus Pharmaceuticals.

Q

What sector and industry does Tarsus Pharmaceuticals (TARS) operate in?

A

Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.